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Abstract Quantitative sensory testing (QST) is a nonin-
vasive method of assessing sensory and pain perception
that has been used in the past 30 years primarily for
analysis of cutaneous and mucosal perception. In recent
years, several published studies have demonstrated that
QST may be useful in the analysis of painful musculo-
skeletal disorders as well. Based on the results of these
studies, it can be postulated that QST may be useful in
the analysis of the pathogenesis, classification, and
differential diagnosis of musculoskeletal disorders. How-
ever, due to the diverse ethiopathogenetic basis of these
disorders, a broad range of QST test batteries may be
necessary to analyze the various musculoskeletal disease
entities. This review analyzes published studies on this
subject and summarizes current information on altered
sensory and pain perception available for some of the
most common musculoskeletal disorders. At present,
QST remains primarily a research tool but may be useful
in differential diagnosis in indicating the presence of
central sensitization and for clinical monitoring of
disease progression or treatment response.
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Introduction
Quantitative sensory testing (QST) is a term used to
describe different forms of psychophysical testing of skin,
mucosa, or muscle tissue that assess sensory and pain
perception pathways. Various forms of QST test batteries
have been introduced that encompass various methods of
sensory and pain detection threshold determination, as well
as suprathreshold and pain tolerance threshold determina-
tion under different testing paradigms [1￿, 2]. They
typically include warm and cold perception threshold
testing, heat pain, and cold pain detection threshold testing
using a thermotesting device such as TSA-II (Medoc Ltd.,
Ramat Yishai, Israel), CASE IV (WR Medical Electronics
Co., Stillwater, MN) or MSAThermotest (Somedic, Mörby,
Sweden); mechanical detection threshold determination
using von Frey filaments and a pressure algometer;
vibration detection threshold determination using a tuning
fork or any of the several commercially available vibration
threshold testers; allodynia testing using a cotton swab or
paintbrush; and dynamic wind-up testing using repeated
skin stimulation with a predefined force and tip size.
Several additional invasive tests for the quantification of
muscular pain perception using electrical stimulation or
intramuscular injection of hypertonic saline also have been
described [3￿]. This testing is rather expensive and time
consuming but provides comprehensive information on the
state of peripheral sensory and pain perception as well as
central sensitization.
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DOI 10.1007/s11926-010-0131-0To exclude the influence of the state of peripheral
nociceptors and solely test neuronal transduction of
peripheral sensory input, its processing, and its perception
in the spinal cord and central nervous system, one can test
the neurophysiologic response to peripheral electrical
stimulation of the skin using a peripheral nerve stimulator
r o u t i n e l yu s e di nr e g i o n a la n e s t h e s i ao rc o m m e r c i a l l y
available experimental devices (Neurometer; Neurotron,
Baltimore, MD). Similar testing has been applied success-
fully to test muscle tissue sensitivity to electrical stimula-
tion [4]. Specific testing of pain fibers (A-δ and C fibers) is
possible using laser-evoked potentials by means of induc-
ing heat pain without actual skin contact [5]. To test a
mechanism of endogenous analgesia, also known as diffuse
noxious inhibitory control (DNIC), it is possible to test
local or referred pain perception while providing a
conditioning stimulus at the same time, based on the
principle of pain inhibiting pain [6￿]. Although many
variations of this test have been described, the most
commonly used are the induction of DNIC by immersion
in ice water (so-called cold pressor test), or hot water on a
different/distant body part than the one on which the pain
perception testing is being performed.
All these different methods of QST can be used to do the
following:
1. Study the anatomic and physiologic basis of normal
and pathological sensory and pain perception
2. Discern different pain syndromes clinically presenting
with similar symptomatic paradigms
3. Allow for a qualitative and semiquantitative assessment
of those illnesses that show poor correlation of patients’
symptoms and signs with respective pathological
changes, or have no obvious changes
4. Evaluate patients’ response to pharmacologic or non-
pharmacologic therapeutic approaches under experi-
mental and clinical conditions.
QST is considered to be semi-objective because it is
dependent on the patient’s perception and reporting and
relies on his or her cooperation and attentiveness during the
testing procedure [1￿]. As discussed in the review articles
by Rolke et al. [2] and Backonja et al. [1￿], standardization
of the experimental protocol and environmental conditions
under which the testing is being performed is essential for
obtaining reproducible results comparable to normative
data and data from different testing laboratories/centers.
Rationale for Quantitative Sensory Testing
in Musculoskeletal Pain Disorders
Musculoskeletal pain is one of the most common reasons
for seeking physicians’ help. The term encompasses a wide
range of disease states, ranging from well-defined illnesses
such as osteoarthritis, rheumatoid arthritis (RA), and gout
to more unspecific regional and generalized pain syndromes
such as epicondylalgia, fibromyalgia, and finally pain
related to the spine such as neck and low back pain. The
pathophysiology of many painful conditions is unspecific
and/or unclear, whereas different etiologic/pathogenetic
mechanisms causing pathological changes in muscles,
bones, joints, and ligaments have been identified in great
detail in others. However, in most cases, the exact etiologic/
pathogenetic mechanism for a given pain problem is
seldom obvious or known. This broad etiologic basis for
pain development in musculoskeletal disorders is further
complicated by the pathophysiologic relevance of various
psychological and social factors, as well as the potential
for central sensitization of sensory and nociceptive
pathways, which may lead to further increases in the
perceived intensity and distribution of pain. Central
sensitization represents an augmentation of pain signal-
ing in neurons and neuronal circuits in pathways related
to nociception. It is caused by increases in membrane
excitability and synaptic efficacy; loss of neuronal
inhibition, including descending pain inhibition; and
potentially by a dysfunction in the top-down regulation
within the central nervous system. Objective findings for
abnormal central pain processing range from muscle
hyperalgesia to generalized and polymodal hyperalgesia,
as well as referred pain. These features in turn share
many common characteristics with neuropathic pain, all
of which can be detected using QST.
For that reason, various methods of QST were applied in
recent years to investigate the pathophysiologic mecha-
nisms of musculoskeletal pain, primarily using experimen-
tal muscle pain paradigms [7]. However, many studies also
have been conducted and published in which QST has
been used to analyze pain pathways and mechanisms
involved in musculoskeletal disease states in humans
[3￿]. For some of these conditions, such as fibromyalgia
and myofascial pain, certain tests (eg, pressure algometry
of tender or trigger points) may contribute to the illness
classification and/or diagnosis [8]. In other diseases, the
testing has been used primarily to try to elucidate potential
underlying pathogenetic mechanisms, as in the case of low
back pain, primary and secondary restless legs syndrome
associated with small-fiber neuropathy [9￿, 10], or
temporomandibular joint pain [11]. It is noteworthy that
such testing can be performed not only locally at the site
of musculoskeletal pain but also at the site of referred
pain. However, a comprehensive analysis of peripheral
s e n s o r yp e r c e p t i o na n dn o c i c e p t i o ni np a t i e n t sw i t h
various musculoskeletal disorders, such as the one
performed for neuropathic pain disorders in Germany
[2], has not been undertaken thus far.
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Osteoarthritis
Osteoarthritic pain has been classically attributed to joint
damage. This simplistic view has been questioned in view
of poor correlations between objective markers and symp-
tomatology in this condition [12]. Findings from QST
studies in patients with osteoarthritis also support an
additional role for abnormal central pain and sensory
processing in the maintenance and development of chronic
pain in osteoarthritis.
Deficits in proprioception have been shown not only in
the osteoarthritic joint(s) but also in distal body areas [13].
Furthermore, several studies reported lower and upper
extremity deficits in vibration perception in individuals
with knee or hip osteoarthritis [14, 15]. This suggests an
extensive effect of a local ostheoarthritic process on the
sensory system. Experimental animal studies demonstrated
increased expression of the neuromodulatory peptide
substance P in peripheral tissue affected by osteoarthritis
and an increased expression of calcitonin gene-related
peptide in the dorsal root ganglia in a rat model of chronic
knee inflammation, which may suggest increased suscepti-
bility to central sensitization of neuronal pathways.
Further QST studies provide additional evidence for
altered pain processing in osteoarthritic patients. As early as
1981, painful electrical stimulation in patients with osteo-
arthritis of the knee indicated decreased pain thresholds on
the affected side [16]. An intramuscular injection of
hypertonic saline into the anterior tibialis muscle demon-
strated increased sensitivity to painful stimulation in
patients with osteoarthritis of the lower extremity as
compared with healthy controls. In a recent study, patients
with osteoarthritis were found to have significantly lower
perception threshold for punctate stimuli and hyperalgesia
to noxious punctate stimuli in areas of referred pain [17].
This finding correlates well with increased brainstem
activity induced by stimulation of areas of referred pain,
as demonstrated by using functional brain imaging in
patients with osteoarthritis, thus further supporting the role
of central sensibilization in osteoarthritis. On the other
hand, pressure pain thresholds measured with pressure
algometry at various body areas independent from the
osteoarthritic site were statistically significantly higher in
patients with osteoarthritis compared with healthy individuals
[18]. Furthermore, patients with osteoarthritis demonstrated a
lack of analgesic effects of DNIC on pressure-induced pain
[19], which normalized after successful hip replacement
(i.e., the cessation of ongoing nociceptive input). These
complex and somewhat contradictory results suggest that
different underlying etiopathogenetic mechanisms may con-
tribute to symptom expression in a common clinical
syndrome such as osteoarthritis-related pain. Moreover, they
emphasize the need for further systematic investigation of
the peripheral and central sensory and nociceptive processing
in chronic pain conditions.
Rheumatoid Arthritis
A mild symmetric sensory or sensorimotor axonal poly-
neuropathy has been detected in RA patients, mostly
expressing itself as a subclinical entity associated with
axonal pathology [20]. Vibration perception was altered in
one third of the patients, suggesting involvement of A-β
fibers, but the condition of smaller fibers (C fibers) was not
analyzed in this study. In another study of patients with RA,
it was determined that pressure pain thresholds in non-
affected body parts were significantly lower than they were
in healthy individuals, suggesting that the function of A-δ
fibers might also be negatively affected by RA [18]. An
admittedly small study on RA patients carried out by
Lanzillo et al. [21] in 1998 (n=28) showed a subclinical
peripheral nerve dysfunction. A total of 65% of patients
exhibited electrophysiologic findings consistent with sen-
sorimotor neuropathy. In addition, there was a moderate
loss of myelinated fibers in 75% of nerve biopsy samples,
and all biopsied patients showed an increased number of
endoneural and perineural vessels and some signs of axonal
degeneration [21]. Furthermore, capsaicin-induced axonal
reflex vasodilatation in patients with RA was significantly
greater over the affected wrists, but not the forearms,
compared with age-matched healthy controls [22]. This
phenomenon was associated with a slight increase in pain
perception measured on a visual analogue scale in RA
patients. One reason for the development of this polyneur-
opathy could be a disease-induced dysfunction of the
hypothalamic-hypophyseal axis and its influence on the
balance between inflammation-stimulating sensory nerve
endings and inflammation-suppressing symphathetic nerve
endings. The evaluation of the somatosensory dysfunction
in RA is further complicated by its potential to develop a
drug-induced secondary peripheral neuropathy. An example
of this confounding component is a sensorimotor dysfunc-
tion reported in RA patients treated with etanercept [23].
Assessment of pain sensitivity in RA should also take into
considerationitsfrequentcomorbiditywithconditionssuchas
fibromyalgia syndrome, which can lead to increased clinical
and spontaneous pain and can result in a generalized hyper-
algesia [24]. In contrast, an imaging study using positron
emission tomography showed a dampened brain response to
painful heat stimulation in patients with RA alone compared
with healthy controls and with patients with fibromyalgia
syndrome–like pain, with RA patients being the least
sensitive to nociceptive stimuli [25].
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Response to painful stimuli was analyzed in two studies of
patients with ankylosing spondylitis, one of which found an
increased threshold to pressure pain measured with a
pressure algometer compared with healthy controls [18].
The other found no difference in pain sensitivity to blunt
pressure in comparison with healthy controls [26]. Al-
though response to additional sensory or painful stimuli
was not investigated, these limited results suggest that in
ankylosing spondylitis, neuronal pathways involved in
pressure pain perception are neither peripherally nor
centrally sensitized.
Fibromyalgia
Fibromyalgia has been classified by chronic widespread
pain and at least 11 of 18 painful tender points on palpation,
although a new classification based on symptom load was
suggested recently [27]. Using QST paradigms, fibromyal-
gia patients also show an increased pain response to painful
mechanical stimuli [28, 29]. Decreased heat pain thresholds
of fibromyalgia patients compared with controls also have
been shown by multiple groups [30, 31], as have reduced
cold pain thresholds [31] and reduced tolerance to the cold
pressor test and the tourniquet ischemia test [8]. Sensitivity to
innocuous warmth and cold stimuli and nonpainful electrical
stimulation seems unaffected [32]. This pattern of hyper-
responsiveness to sensory stimuli has also been shown for
auditory stimulation.
Importantly, fibromyalgia-associated hyperalgesia is not
limited to the so-called tender points and mechanical
stimulation but is widespread and present for multiple
sensory domains, as demonstrated independently by Staud
et al. [33] and Carli et al. [8]. They and other authors
suggested central sensitization as a contributing pathophys-
iologic factor [30, 32]. Accordingly, wind-up as an
experimental correlate for central sensitization can be
evoked in controls and in patients with fibromyalgia
syndrome, but clear differences between controls and
patients can be observed. The magnitude of the sensory
response to the first stimulus within a series is greater in
fibromyalgia, as is the amount of temporal summation
within a series [34].
Hyperalgesia in fibromyalgia patients also has been
shown to be independent of the stimulation paradigm
(ascending stimulation vs random stimulation) [30], and
thresholds to elicit the potentially more “objective” noci-
ceptive flexion reflex in patients with fibromyalgia are
decreased. These findings indicate that one can assume that
hyperalgesia and thus central sensitization in fibromyalgia
do not primarily result from psychological factors but rather
from a hyperexcitable nociceptive environment, although
there is also some evidence for the modulatory influence of
psychological factors such as catastrophizing [35].
Several mechanisms have been implicated in the
development of this phenomenon. An active involvement
of excitatory amino acid neurotransmitter systems in this
hyperexcitability is suggested by the finding that ketamine,
an N-methyl-D-aspartate receptor antagonist, reduces mus-
cle pain, temporal summation, and referred pain in
fibromyalgia patients [36]. The relevance of ongoing
peripheral input to maintain generalized sensitization was
recently shown by Staud et al. [37￿￿]. Efferent DNIC, also
referred to as heterotopic noxious conditioning stimulation,
is also suppressed in fibromyalgia patients. Such dimin-
ished DNIC response has been documented under various
DNIC-inducing paradigms, such as ice and hot water
noxious stimulation and electrical noxious stimulation,
and is further supported by recent functional imaging
findings [38, 39].
Epicondylalgia
Fernandez-Carnero et al. [40] have analyzed local and
general skin sensitivity to pressure stimuli in patients with
clinical or experimental lateral epicondylalgia. Patients with
epicondylalgia showed significantly lower pressure pain
thresholds and larger referred pain areas upon stimulation
of active trigger points in the forearm extensor muscles
when compared with controls. Furthermore, not only do
active trigger points with a typical referred pain pattern
show an increased sensitivity to pressure, but so-called
latent trigger points on both the ipsilateral and contralateral
side (which are not painful per se but may cause
pathological muscle dysfunction upon activation) also
demonstrate increased sensitivity to painful pressure stim-
uli. Interestingly, this hyperalgesia was confined to pressure
stimuli, with normal reactions to vibration or thermal stimuli
[41]. However, upon painful stimulation (weightlifting),
pain intensity in the local and referred pain areas was
significantly increased [42]. Repeated muscle contractions
resulted in altered somatosensory functions in the affected
arm and unaffected arm. Tactile perception thresholds,
which were initially not altered in the areas of primary and
referred pain, increased significantly following pain
provocation in the referred pain area only and normalized
following injection of a local anesthetic, indicating that
the sensitivity to light touch was altered by nociceptive
input from the affected arm.
Temporomandibular Disorders
Compared with controls, patients with temporomandibular
disorders (TMDs) have significantly lower thermal pain
threshold, ischemic pain threshold, and ischemic pain
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extremities [43]. Thermal pain tolerance also tends to be
lower. Furthermore, TMD patients show increased ther-
mal C-fiber–mediated temporal summation compared
with pain-free individuals and report higher pain levels
compared with controls in response to sustained noxious
heat pulses applied to the face or the forearm. Interest-
ingly, individuals with TMDs and those who are pain
free are equally able to distinguish and detect small
increments of heat applied to existing painful thermal
stimulation [44]. A general hyperalgesia in female patients
with TMDs was also confirmed by another independent
group [45]. Interestingly, a recent study using the German
standardized QST protocol found two different QST
profile patterns among TMD patients that correlated with
their number of tender points, suggesting an overlap in
pathophysiology with fibromyalgia [46￿].
Chronic Neck Pain
Analysis of the sensory and deep muscle perception in
chronic neck pain revealed an interesting finding.
Pressure pain threshold levels were significantly de-
creased bilaterally over the masseter, temporalis, and
upper trapezius muscles, and in the C5-C6 zygapophy-
seal joints in patients with mechanical chronic neck pain
compared with controls [47]. However, the testing
performed over the anterior tibialis muscle showed no
increased sensitivity to nonpainful or painful stimuli. This
finding suggests a spinal level rather than a supraspinal
sensitization in chronic neck pain.
Low Back Pain
The term low back pain encompasses an array of etiologic
entities that all symptomatically converge as pain in the
lower dorsal segment of the trunk with or without radicular
or pseudoradicular radiation to the lower extremity. This
pain can originate from compressed dorsal nerve roots as a
consequence of prolapsed intervertebral disc material and/
or degenerative narrowing of the intervertebral foramina
but may have predominantly muscular or joint origin and
remain clinically unspecific in most patients. Poor correla-
tion between radiologic imaging and clinical symptoms, as
well as the lack of specificity of neurophysiologic testing
further preclude a definitive etiopathogenetic diagnosis in
many cases.
Thus, clinically, chronic low back pain (CLBP) shows
similarities to conditions such as fibromyalgia (only
localized and not generalized) and has common charac-
teristics with neuropathic pain in cases of established
radicular pain. A clear distinction between a (predomi-
nantly) neuropathic (radicular) or referred (nondermato-
mal) pain radiation in the leg or the identification of
markers for generalized central sensitization using QST
would be of great value in the classification of this type
of pain.
Several QST studies have addressed this interesting
question. In a study published in 1999, Clauw et al. [48]
assessed whether pressure pain sensitivity at thumbnail and
various psychological and imaging factors correlated well
with clinical pain and functional status in CLBP. The
pressure pain sensitivity, as a measure of local tenderness to
blunt stimuli, was found to be a significant predictor of a
clinically relevant pain magnitude. In an imaging study
using functional MRI, a small and selected sample of
patients with nonspecific CLBP showed similar overall
tenderness as patients with fibromyalgia, and a similarly
augmented response in brain activity to painful stimulation
as patients with fibromyalgia when compared with healthy
controls [49]. Another study demonstrated a correlation
between increasing heat pain sensitivity, female sex, and
increased psychological burden in a cohort of tertiary care
patients with CLBP (unfortunately without a control group)
[50]. Taken together, one could conclude that in at least a
subgroup of patients with CLBP, central sensitization may
be a relevant pathophysiologic factor.
In a pilot trial of QST of patients with CLBP
conducted by Freynhagen et al. [9￿], the authors reported
a distinction in vibration detection thresholds among the
“radicular” and “nonradicular” patients. However, they
also reported a considerable rate of sensory loss in the
“nonradicular” group (>40%). Furthermore, the overall
number of participants was again small. These findings led
to a constructive discussion focusing on a putative initial
distinction and later confluence of mechanogenic, neuro-
pathic, and psychogenic learned pain, further influenced
by mechanisms of central sensitization, as the probable
main components of the underlying pathophysiologic
mechanisms leading to a clinically relevant lower back
pain syndrome.
Conclusions
Most of the studies of invasive or noninvasive sensory
testing of the skin or deep tissues in patients with
musculoskeletal disorders have been performed primarily
in an attempt to analyze the pathogenesis of the underlying
illness. This is also the reason for the diverse methodology
applied in these studies, thus making comparison of results
difficult. Whether an approach to QST similar to that of the
German Network on Neuropathic Pain also makes sense for
musculoskeletal pain remains an open question and
challenge. One could argue that this approach to neuro-
pathic pain already yielded its first success in the case of
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testing cannot provide a final diagnosis. The best
example is a recent publication of differential warmth
and cold perception in patients with secondary restless
legs syndrome associated with small-fiber neuropathy as
compared with primary restless legs syndrome patients
[10], thus making an invasive diagnostic skin biopsy
unnecessary. However, this structured approach seems to
be only a first step toward development of a mechanism-
based algorithm to diagnose and treat neuropathic pain.
In musculoskeletal pain, the current data on QST show
central sensitization to be a potential common theme for
different clinical conditions. This varies from localized to
generalized presentations but may be caused by similar
mechanisms. The role of peripheral input and/or periph-
eral sensitization in the development and maintenance of
central sensitization and chronic pain is far from
unequivocal, but there is evidence for the role of
ongoing (nociceptive) stimulation, at least in some of
these conditions.
It is tempting to suggest a standardized approach to
QST in musculoskeletal pain that would require a broad
agreement on the set of tests and stimulus modalities that
would be routinely performed. Such a QST test battery
for musculoskeletal disorders should focus on detecting
central sensitization of sensory and pain perception in the
affected body parts, as well as on the assessment of
descending inhibitory antinociceptive pathway activity.
In addition, the effects of potential ongoing peripheral
sensory and nociceptive stimulation should be assessed.
The development of easy-to-use, validated, and simple
test paradigms controlling for psychological comorbidity
remains another challenge.
Finally, the use of current QST procedures could be
clinically very useful as a monitoring tool in patients taking
medications that typically and frequently affect the periph-
eral nervous system, as these neuropathic changes could be
detected easily in the early stages of their pathogenetic
development using QST testing. Patients with comorbid
musculoskeletal conditions may also benefit from QST by
shifting the diagnostic and therapeutic focus from local
pathology to generalized changes in pain perception in
these disease states.
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